A
Amberstone Biosciences
Discovers novel immunotherapies through innovative technologies and creative partnerships
About Amberstone Biosciences
Amberstone Biosciences operates in the biotechnology sector, focusing on drug discovery and immunotherapy. The company is dedicated to developing transformative therapeutic antibodies using innovative technologies and creative partnerships. Amberstone Biosciences serves patients with unmet medical needs, aiming to pioneer a new wave of therapeutic breakthroughs. The company's business model involves leveraging its single cell analysis platform to identify and develop novel antibodies, which are then brought to market through collaborations and partnerships. Revenue is generated through licensing agreements, research collaborations, and potential future sales of developed therapies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Irvine, United States
- Employees
- 15
- Open positions
- None listed
- Dealroom signal
- 70.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
Knowledge graph
News
More headlines
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2022 | $12M | $48M | Xiamen Changrong Investment Management · Lifespan Investments · Cowin Venture · Sinovation Ventures | ↗ |
| GRANTOther financing | Apr 2021 | $1.1M | — | US National Science Foundation | ↗ |
Growth signals
Latest recorded traffic for Amberstone Biosciences is 470 monthly website visits, down 70.6% over the last three months. Amberstone Biosciences's team grew 15.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Amberstone Biosciences in the Irvine ecosystem
The Amberstone Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
US National Science Foundation
Series A5 investors entered at this stage
Cowin Venture
Sinovation Ventures- VBViva BioInnovator
- XMXiamen Changrong Investment Management
- LILifespan Investments
Other known investors2 additional known investors
University of California, Irvine
Small Business Innovation Research
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Amberstone Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Amberstone Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.